2 major Indian pharmas to start intranasal COVID-19 vaccine trial |
Serum Institute of India and Bharat Biotech are expected to pursue late stage clinical trials of intranasal COVID-19 vaccines in the coming months. Making this announcement, Health Minister Dr Harsh Vardhan said on 18th October said that the late-stage trial generally involves thousands of participants, sometimes 30,000 to 40,000. Of the vaccines currently in Phase 3 trials, all are administered by injection. On 17th October, India`s Dr Reddy`s Laboratories Ltd and the Russian Direct Investment Fund said they have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine. India`s Coronavirus infections rose by another 61,871 on 17th October. However, the health ministry sees a trend of steadily declining active cases. The Indian Council of Medical Research said it will revisit its protocol for COVID-19 treatment after the WHO found some of the commonly used drugs, including Remdesivir, had little or no impact on a patient`s chances of surviving.
|
|
|
|